A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Partici… (NCT07691762) | Clinical Trial Compass
Not Yet RecruitingPhase 3
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
China690 participantsStarted 2026-07
Plain-language summary
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
Participants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age 18-75 years old, male or female;
. Diagnosis confirmed HCC by pathologically or clinically;
. At least one measurable lesion;
. Child-Pugh liver function grade A;
. ECOG-PS score: 0 or 1;
. Eligible for TACE treatment as assessed by the investigator;
. Participants with HBV or HCV infection must be on and remain on standard antiviral therapy throughout the study period;
. Consent to contraception
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Progression-free survival (PFS) assessed by investigator
Timeframe: Until progression, assessed up to approximately 2 years
. Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma or mixed cholangiocarcinoma / hepatocellular carcinoma; Participants with other malignancies currently or within the past 5 years;
. Participants with any active, known or suspected autoimmune disorder;
. Participants with hypertension which cannot be well controlled by antihypertensives;
. Uncontrolled cardiac diseases or symptoms;
. Participants with hepatic encephalopathy;
. Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment
. History of gastrointestinal perforation and/or fistula,
. Participants with other potential factors that may affect the study results.